IRWD
Ironwood Pharmaceuticals, Inc.
Price Chart
Latest Quote
$3.91
+0.05 (+1.30%)
Current Price
| Previous Close | $3.86 |
| Open | $3.80 |
| Day High | $4.00 |
| Day Low | $3.80 |
| Volume | 1,683,924 |
Stock Information
| Shares Outstanding | 164.61M |
| Total Debt | $597.36M |
| Cash Equivalents | $220.47M |
| Revenue | $361.51M |
| Net Income | $102.18M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $632.12M |
| P/E Ratio | 6.19 |
| EPS (TTM) | $0.62 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.02B |
| Sales | $361.51M |
| Income | $102.18M |
| Book/sh | $-1.32 |
| Cash/sh | $1.34 |
| Employees | 100 |
Financial Ratios
| Quick Ratio | 1.38 |
| Current Ratio | 1.41 |
Returns & Margins
| ROA | 33.15% |
| Gross Margin | 75.20% |
| Operating Margin | 68.10% |
| Profit Margin | 28.26% |
Ownership
| Insider Ownership | 3.16% |
| Institutional Ownership | 99.01% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 2.67 |
| P/S | 1.75 |
| P/B | -2.91 |
Analyst Data
| Recommendation | none |
| Target Price | $6.10 |
Technical Indicators
| SMA20 | $3.54 |
| SMA50 | $3.87 |
| SMA200 | $3.32 |
| RSI | 67.19 |
| ATR | 0.2121 |
| Shares Float | 134.89M |
| Short Float | 9.97% |
| Short Ratio | 5.57 |
| Volatility | 0.24 |
| Rel Volume | 0.80 |
Performance History
| Week | +9.09% |
| Month | -1.54% |
| Quarter | +20.38% |
| 6 Months | +18.89% |
| YTD | -10.07% |
| Year | +426.03% |
| 3 Years | -64.35% |
| 5 Years | -66.52% |
| 10 Years | -62.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $3.84 | 1,659,093 |
| 2026-06-24 | $3.91 | 1,764,500 |
| 2026-06-23 | $3.86 | 1,445,000 |
| 2026-06-22 | $3.82 | 2,523,900 |
| 2026-06-18 | $3.54 | 4,942,500 |
| 2026-06-17 | $3.52 | 1,629,200 |
| 2026-06-16 | $3.66 | 1,825,400 |
| 2026-06-15 | $3.69 | 2,004,900 |
| 2026-06-12 | $3.65 | 1,868,700 |
| 2026-06-11 | $3.63 | 2,781,400 |
| 2026-06-10 | $3.35 | 1,873,900 |
| 2026-06-09 | $3.22 | 2,029,500 |
| 2026-06-08 | $3.29 | 1,502,100 |
| 2026-06-05 | $3.31 | 1,334,400 |
| 2026-06-04 | $3.40 | 1,876,500 |
| 2026-06-03 | $3.24 | 2,685,900 |
| 2026-06-02 | $3.28 | 1,900,500 |
| 2026-06-01 | $3.46 | 1,699,500 |
| 2026-05-29 | $3.57 | 2,034,700 |
| 2026-05-28 | $3.60 | 1,882,100 |
| 2026-05-27 | $3.71 | 2,944,000 |
| 2026-05-26 | $3.90 | 2,783,900 |
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
đ° Latest News
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Zacks âĸ 2026-06-25T12:40:00Z
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Zacks âĸ 2026-06-11T13:38:00Z
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?
Insider Monkey âĸ 2026-06-02T13:58:13Z
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?
Insider Monkey âĸ 2026-05-20T20:42:59Z
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T05:07:54Z
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-07T12:50:18Z
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Zacks âĸ 2026-04-21T14:37:00Z
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why
Insider Monkey âĸ 2026-03-31T11:34:22Z
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
Zacks âĸ 2026-03-30T16:11:00Z
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
Zacks âĸ 2026-03-27T15:30:08Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $296,151,000 | $351,410,000 | $442,735,000 | $410,596,000 |
| Operating Revenue | $296,151,000 | $351,410,000 | $442,735,000 | $410,596,000 |
| Reconciled Cost Of Revenue | - | - | - | $0 |
| Cost Of Revenue | - | - | - | $0 |
| Expenses | ||||
| Interest Expense | $32,746,000 | $33,034,000 | $21,629,000 | $7,598,000 |
| Total Expenses | $177,392,000 | $255,693,000 | $274,399,000 | $160,259,000 |
| Other Income Expense | $-20,064,000 | $-1,953,000 | $-1,113,747,000 | $182,000 |
| Other Non Operating Income Expenses | $193,000 | $640,000 | - | - |
| Net Non Operating Interest Income Expense | $-28,670,000 | $-28,566,000 | $-2,658,000 | $1,903,000 |
| Interest Expense Non Operating | $32,746,000 | $33,034,000 | $21,629,000 | $7,598,000 |
| Operating Expense | $177,392,000 | $255,693,000 | $274,399,000 | $160,259,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $24,017,000 | $880,000 | $-1,002,239,000 | $175,065,000 |
| Net Interest Income | $-28,670,000 | $-28,566,000 | $-2,658,000 | $1,903,000 |
| Interest Income | $4,076,000 | $4,468,000 | $18,971,000 | $9,501,000 |
| Normalized Income | $40,020,030 | $2,928,470 | $-122,378,870 | $174,938,776 |
| Net Income From Continuing And Discontinued Operation | $24,017,000 | $880,000 | $-1,002,239,000 | $175,065,000 |
| Total Operating Income As Reported | $98,502,000 | $93,124,000 | $-945,430,000 | $250,337,000 |
| Net Income Common Stockholders | $24,017,000 | $880,000 | $-1,002,239,000 | $175,065,000 |
| Net Income | $24,017,000 | $880,000 | $-1,002,239,000 | $175,065,000 |
| Net Income Including Noncontrolling Interests | $24,017,000 | $880,000 | $-1,031,559,000 | $175,065,000 |
| Net Income Continuous Operations | $24,017,000 | $880,000 | $-1,031,559,000 | $175,065,000 |
| Pretax Income | $70,025,000 | $65,198,000 | $-948,069,000 | $252,422,000 |
| Special Income Charges | $-20,257,000 | $-2,593,000 | $-1,113,766,000 | $0 |
| Interest Income Non Operating | $4,076,000 | $4,468,000 | $18,971,000 | $9,501,000 |
| Operating Income | $118,759,000 | $95,717,000 | $168,336,000 | $250,337,000 |
| Average Dilution Earnings | - | $0 | $0 | $4,449,000 |
| Gross Profit | - | - | - | $410,596,000 |
| Net Income Discontinuous Operations | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $0.15 | $0.01 | $-6.45 | $0.96 |
| Basic EPS | $0.15 | $0.01 | $-6.45 | $1.13 |
| Other | ||||
| Tax Effect Of Unusual Items | $-4,253,970 | $-544,530 | $-233,886,870 | $55,776 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $124,909,000 | $102,836,000 | $188,882,000 | $261,256,000 |
| Total Unusual Items | $-20,257,000 | $-2,593,000 | $-1,113,747,000 | $182,000 |
| Total Unusual Items Excluding Goodwill | $-20,257,000 | $-2,593,000 | $-1,113,747,000 | $182,000 |
| Reconciled Depreciation | $1,881,000 | $2,011,000 | $1,575,000 | $1,418,000 |
| EBITDA (Bullshit earnings) | $104,652,000 | $100,243,000 | $-924,865,000 | $261,438,000 |
| EBIT | $102,771,000 | $98,232,000 | $-926,440,000 | $260,020,000 |
| Diluted Average Shares | $162,983,000 | $160,084,000 | $155,435,000 | $186,312,000 |
| Basic Average Shares | $161,842,000 | $159,083,000 | $155,435,000 | $154,366,000 |
| Diluted NI Availto Com Stockholders | $24,017,000 | $880,000 | $-1,002,239,000 | $179,514,000 |
| Tax Provision | $46,008,000 | $64,318,000 | $83,490,000 | $77,357,000 |
| Restructuring And Mergern Acquisition | $20,257,000 | $2,593,000 | $18,317,000 | $0 |
| Research And Development | $95,136,000 | $111,421,000 | $116,085,000 | $44,265,000 |
| Selling General And Administration | $82,256,000 | $144,272,000 | $158,314,000 | $115,994,000 |
| Minority Interests | - | $0 | $29,320,000 | $0 |
| Other Special Charges | - | - | $1,095,449,000 | - |
| Gain On Sale Of Security | - | - | $19,000 | $182,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-263,875,000 | $-304,195,000 | $-349,977,000 | $652,378,000 |
| Total Assets | $396,901,000 | $350,908,000 | $471,073,000 | $1,100,519,000 |
| Total Non Current Assets | $122,723,000 | $168,540,000 | $237,785,000 | $319,893,000 |
| Other Non Current Assets | $4,502,000 | $5,923,000 | $3,608,000 | $1,332,000 |
| Non Current Deferred Assets | $103,433,000 | $144,234,000 | $212,324,000 | $283,661,000 |
| Non Current Deferred Taxes Assets | $103,433,000 | $144,234,000 | $212,324,000 | $283,661,000 |
| Goodwill And Other Intangible Assets | $2,040,000 | $2,860,000 | $3,682,000 | $0 |
| Other Intangible Assets | $2,040,000 | $2,860,000 | $3,682,000 | - |
| Current Assets | $274,178,000 | $182,368,000 | $233,288,000 | $780,626,000 |
| Other Current Assets | $11,977,000 | $11,923,000 | $12,012,000 | $7,715,000 |
| Receivables | $46,745,000 | $81,886,000 | $129,122,000 | $115,458,000 |
| Accounts Receivable | $46,745,000 | $81,886,000 | $129,122,000 | $115,458,000 |
| Cash Cash Equivalents And Short Term Investments | $215,456,000 | $88,559,000 | $92,154,000 | $656,203,000 |
| Cash And Cash Equivalents | $215,456,000 | $88,559,000 | $92,154,000 | $656,203,000 |
| Restricted Cash | - | - | $0 | $1,250,000 |
| Non Current Accounts Receivable | - | - | - | $14,589,000 |
| Hedging Assets Current | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $369,224,000 | $495,429,000 | $605,715,000 | - |
| Total Debt | $597,802,000 | $599,481,000 | $715,538,000 | $415,915,000 |
| Long Term Debt And Capital Lease Obligation | $394,870,000 | $596,292,000 | $512,852,000 | $412,850,000 |
| Long Term Debt | $385,000,000 | $583,988,000 | $498,309,000 | $396,251,000 |
| Current Debt And Capital Lease Obligation | $202,932,000 | $3,189,000 | $202,686,000 | $3,065,000 |
| Current Debt | $199,680,000 | - | $199,560,000 | - |
| Other Current Borrowings | $199,680,000 | - | $199,560,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $658,736,000 | $652,243,000 | $817,368,000 | $448,141,000 |
| Total Non Current Liabilities Net Minority Interest | $416,518,000 | $613,397,000 | $541,267,000 | $422,616,000 |
| Other Non Current Liabilities | $21,648,000 | $17,105,000 | $28,415,000 | $9,766,000 |
| Current Liabilities | $242,218,000 | $38,846,000 | $276,101,000 | $25,525,000 |
| Other Current Liabilities | $9,407,000 | $4,418,000 | $6,197,000 | $3,607,000 |
| Current Deferred Liabilities | $1,107,000 | $2,032,000 | $2,620,000 | - |
| Payables And Accrued Expenses | $17,182,000 | $14,660,000 | $44,661,000 | $6,585,000 |
| Interest Payable | $4,437,000 | $4,771,000 | $5,953,000 | $188,000 |
| Payables | $3,825,000 | $2,648,000 | $9,074,000 | $1,139,000 |
| Total Tax Payable | $927,000 | $521,000 | $1,244,000 | $656,000 |
| Accounts Payable | $2,898,000 | $2,127,000 | $7,830,000 | $483,000 |
| Equity | ||||
| Common Stock Equity | $-261,835,000 | $-301,335,000 | $-346,295,000 | $652,378,000 |
| Total Equity Gross Minority Interest | $-261,835,000 | $-301,335,000 | $-346,295,000 | $652,378,000 |
| Stockholders Equity | $-261,835,000 | $-301,335,000 | $-346,295,000 | $652,378,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,060,000 | $923,000 | $-3,031,000 | $0 |
| Other Equity Adjustments | $-1,060,000 | $923,000 | $-3,031,000 | - |
| Retained Earnings | $-1,673,718,000 | $-1,697,735,000 | $-1,698,615,000 | $-696,376,000 |
| Other | ||||
| Ordinary Shares Number | $163,058,316 | $160,205,899 | $156,354,238 | $154,026,949 |
| Share Issued | $163,058,316 | $160,205,899 | $156,354,238 | $154,026,949 |
| Tangible Book Value | $-263,875,000 | $-304,195,000 | $-349,977,000 | $652,378,000 |
| Invested Capital | $322,845,000 | $282,653,000 | $351,574,000 | $1,048,629,000 |
| Working Capital | $31,960,000 | $143,522,000 | $-42,813,000 | $755,101,000 |
| Capital Lease Obligations | $13,122,000 | $15,493,000 | $17,669,000 | $19,664,000 |
| Total Capitalization | $123,165,000 | $282,653,000 | $152,014,000 | $1,048,629,000 |
| Additional Paid In Capital | $1,412,780,000 | $1,395,317,000 | $1,355,195,000 | $1,348,600,000 |
| Capital Stock | $163,000 | $160,000 | $156,000 | $154,000 |
| Common Stock | $163,000 | $160,000 | $156,000 | $154,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $9,870,000 | $12,304,000 | $14,543,000 | $16,599,000 |
| Current Deferred Revenue | $1,107,000 | $2,032,000 | $2,620,000 | - |
| Current Capital Lease Obligation | $3,252,000 | $3,189,000 | $3,126,000 | $3,065,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,590,000 | $14,547,000 | $19,937,000 | $12,268,000 |
| Current Accrued Expenses | $13,357,000 | $12,012,000 | $35,587,000 | $5,446,000 |
| Net PPE | $12,748,000 | $15,523,000 | $18,171,000 | $20,311,000 |
| Accumulated Depreciation | $-8,005,000 | $-8,365,000 | $-8,889,000 | $-10,764,000 |
| Gross PPE | $20,753,000 | $23,888,000 | $27,060,000 | $31,075,000 |
| Leases | $7,443,000 | $7,407,000 | $7,407,000 | $7,407,000 |
| Other Properties | $9,340,000 | $11,028,000 | $13,913,000 | $15,350,000 |
| Machinery Furniture Equipment | $3,970,000 | $5,453,000 | $5,740,000 | $8,318,000 |
| Properties | $0 | $0 | $0 | $0 |
| Minority Interest | - | $0 | $0 | - |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $127,010,000 | $103,407,000 | $183,154,000 | $273,627,000 |
| Operating Activities | ||||
| Operating Cash Flow | $127,044,000 | $103,549,000 | $183,427,000 | $273,763,000 |
| Cash Flow From Continuing Operating Activities | $127,044,000 | $103,549,000 | $183,427,000 | $273,763,000 |
| Operating Gains Losses | $89,000 | $75,000 | $-19,000 | $-180,000 |
| Cash From Discontinued Operating Activities | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-34,000 | $-142,000 | $-273,000 | $-136,000 |
| Investing Cash Flow | $-34,000 | $-142,000 | $-1,026,318,000 | $-136,000 |
| Cash Flow From Continuing Investing Activities | $-34,000 | $-142,000 | $-1,026,318,000 | $-136,000 |
| Cash From Discontinued Investing Activities | - | - | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $216,000 | $-106,970,000 | $277,160,000 | $-237,553,000 |
| Cash Flow From Continuing Financing Activities | $216,000 | $-106,970,000 | $277,160,000 | $-237,553,000 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-126,394,000 |
| Net Other Financing Charges | - | $-2,983,000 | $-29,197,000 | - |
| Net Common Stock Issuance | - | $0 | $0 | $-126,394,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-265,000,000 | $-100,000,000 | $-120,699,000 |
| Issuance Of Debt | $0 | $150,000,000 | $400,000,000 | $0 |
| Interest Paid Supplemental Data | $30,333,000 | $32,563,000 | $13,552,000 | $5,745,000 |
| Income Tax Paid Supplemental Data | $3,543,000 | $8,408,000 | $9,945,000 | $4,615,000 |
| End Cash Position | $215,456,000 | $88,559,000 | $92,154,000 | $657,938,000 |
| Beginning Cash Position | $88,559,000 | $92,154,000 | $657,938,000 | $621,864,000 |
| Effect Of Exchange Rate Changes | $-329,000 | $-32,000 | $-53,000 | $0 |
| Changes In Cash | $127,226,000 | $-3,563,000 | $-565,731,000 | $36,074,000 |
| Proceeds From Stock Option Exercised | $216,000 | $11,013,000 | $6,357,000 | $9,540,000 |
| Net Issuance Payments Of Debt | $0 | $-115,000,000 | $300,000,000 | $-120,699,000 |
| Net Long Term Debt Issuance | $0 | $-115,000,000 | $300,000,000 | $-120,699,000 |
| Long Term Debt Payments | $0 | $-265,000,000 | $-100,000,000 | $-120,699,000 |
| Long Term Debt Issuance | $0 | $150,000,000 | $400,000,000 | $0 |
| Net PPE Purchase And Sale | $-34,000 | $-142,000 | $-273,000 | $-136,000 |
| Purchase Of PPE | $-34,000 | $-142,000 | $-273,000 | $-136,000 |
| Change In Working Capital | $41,338,000 | $739,000 | $11,279,000 | $2,820,000 |
| Change In Other Current Liabilities | $1,593,000 | $-12,432,000 | $-1,488,000 | $8,877,000 |
| Change In Other Current Assets | $2,135,000 | $704,000 | $1,118,000 | $1,480,000 |
| Change In Payables And Accrued Expense | $2,095,000 | $-34,858,000 | $6,505,000 | $-18,754,000 |
| Change In Accrued Expense | $-4,106,000 | $-14,650,000 | $-5,875,000 | $-10,638,000 |
| Change In Payable | $6,201,000 | $-20,208,000 | $12,380,000 | $-8,116,000 |
| Change In Account Payable | $6,201,000 | $-20,208,000 | $12,380,000 | $-8,116,000 |
| Change In Prepaid Assets | $367,000 | $89,000 | $4,220,000 | $3,224,000 |
| Change In Receivables | $35,148,000 | $47,236,000 | $924,000 | $7,993,000 |
| Changes In Account Receivables | $35,148,000 | $47,236,000 | $924,000 | $7,993,000 |
| Other Non Cash Items | $1,668,000 | $1,904,000 | $1,097,509,000 | $1,853,000 |
| Stock Based Compensation | $17,250,000 | $29,850,000 | $32,005,000 | $27,048,000 |
| Deferred Tax | $40,801,000 | $68,090,000 | $72,637,000 | $65,739,000 |
| Deferred Income Tax | $40,801,000 | $68,090,000 | $72,637,000 | $65,739,000 |
| Depreciation Amortization Depletion | $1,881,000 | $2,011,000 | $1,575,000 | $1,418,000 |
| Depreciation And Amortization | $1,881,000 | $2,011,000 | $1,575,000 | $1,418,000 |
| Gain Loss On Sale Of PPE | $89,000 | $75,000 | $0 | $2,000 |
| Net Income From Continuing Operations | $24,017,000 | $880,000 | $-1,031,559,000 | $175,065,000 |
| Common Stock Payments | - | $0 | $0 | $-126,394,000 |
| Net Business Purchase And Sale | - | $0 | $-1,026,045,000 | $0 |
| Purchase Of Business | - | $0 | $-1,026,045,000 | $0 |
| Amortization Cash Flow | - | - | $400,000 | - |
| Amortization Of Intangibles | - | - | $400,000 | - |
| Depreciation | - | - | $1,200,000 | $1,418,000 |
| Gain Loss On Investment Securities | - | - | $-19,000 | $-182,000 |
| Change In Inventory | - | - | - | $0 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-25